Third Pole to collaborate with Janssen’s Actelion

Home » Blog » Third Pole to collaborate with Janssen’s Actelion

Third Pole is a Rosenman Founders Pledge company.


Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson. The collaboration will bring the global resources and know-how of the largest and most respected healthcare company to Third Pole’s simple, convenient, economical, lightweight, and proprietary platform technology, capable of expanding access to potentially life-saving inhaled nitric oxide (iNO) therapy worldwide.

Read the press release